Change the Course of Alzheimer’s Disease Research

Dare to start over and break away from the traditional amyloid precursor protein path. Take a fresh approach to your Alzheimer’s Disease research with optimized in vitro and in vivo models and assays that provide actionable data to drive your drug development from early discovery through late-stage preclinical. Start with any of our cell-based models, transgenic mouse models, aged rat and mouse models, and amnesia models which display pathologies associated with Alzheimer’s Disease (AD). Keep going and breakthrough with our advanced platform of neuroscience translational tools and assays. From cognitive neuroscience studies to AD-associated pathology, get the data you need with our most advanced neurological imaging techniques, behavioral testing platforms and electrophysiology tools.


Accelerate your Alzheimer’s Disease Research in Preclinical Animal Models

Conceptual illustration of neuron cells with glowing link knots in abstract dark space, high resolution 3D illustration.

Learn how to accelerate drug discovery for Alzheimer's Disease with our best practices for preclinical animal studies.
Download the PDF

  • In Vitro Cell-based Assays

    The proper combination of Alzheimer’s disease in vitro assays can deliver critical information delivering insights that serve as better predictors for the transition to in vivo studies. Improve your in vivo success by integrating translational cell-based assays from simple cell proliferation and viability assays to multicellular biochemical and functional assays for high content phenotypic screening using our unique access to Alzheimer’s Disease relevant human primary cells from tissue, blood and differentiated stem cells into your AD discovery program.

  • CVN Mouse Model

    A proven Alzheimer’s Disease model for monitoring behavioral deficits and biochemical hallmarks of AD during aging, this Alzheimer’s animal model exhibits a marked inflammatory component compared other animal models. In CVN mice amyloid plaques and insoluble amyloid beta are detectable in mice at just 9 months of age. CVN mice are biogenic mutants that combine expression of the human APP isoform 770 containing the Swedish (K670N/M671L), Dutch (E693Q), and Iowa (D694N) mutations under the control of the mouse Thy1 promoter and a targeted loss-of-function mutation in the NOS2 gene encoding nitric oxide synthase.

  • Tg2576 Mouse Model

    APPK670/671L, has been linked to early-onset familial Alzheimer’s disease. The Tg2576 Alzheimer's Disease model overexpress this mutant form of amyloid precursor protein. Validated using multiple endpoints including cognitive testing, measurement of the levels of soluble and insoluble beta amyloid, and biomarker measurement using immunohistochemical staining at just 5 months of age.

  • Scopolamine-induced Amnesia Model

    Disruption of the cholinergic system leads to amnesia or memory loss. This Alzheimer’s animal study employs Scopolamine, a muscarinic cholinergic receptor antagonist providing a validated animal model to study impaired learning and memory in Alzheimer’s Disease research.

  • Large Animal Models

    Our Alzheimer's Disease models include large animal models that are used to study higher cognitive function and changes. Large animal models are evaluated using a broad range cognitive test battery that is similar to the CANTAB touchscreen testing methods used in humans.

Characterization of Alzheimer’s Disease Animal Models

Fluorescence view of rat brain slice used in Alzheimer's Disease Research Studies.

Breakthrough your Alzheimer’s Disease research by using these advanced tools to assess next-generation therapeutics.
Watch the webinar


Alzheimer's Disease Research Tools

Tell Us How We Can Support Your Program

 

Frequently Asked Questions (FAQs) for Alzheimer's Disease Research